These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 24912025)

  • 1. Eliciting cytotoxic T-lymphocyte responses from synthetic vectors containing one or two epitopes in a C57BL/6 mouse model using peptide-containing biodegradable microspheres and adjuvants.
    Rubsamen RM; Herst CV; Lloyd PM; Heckerman DE
    Vaccine; 2014 Jul; 32(33):4111-6. PubMed ID: 24912025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
    Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
    Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.
    Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J
    J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
    Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
    J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice.
    Mueller M; Reichardt W; Koerner J; Groettrup M
    J Control Release; 2012 Aug; 162(1):159-66. PubMed ID: 22709589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
    Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
    J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.
    Schlosser E; Mueller M; Fischer S; Basta S; Busch DH; Gander B; Groettrup M
    Vaccine; 2008 Mar; 26(13):1626-37. PubMed ID: 18295941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
    Mossman SP; Evans LS; Fang H; Staas J; Tice T; Raychaudhuri S; Grabstein KH; Cheever MA; Johnson ME
    Vaccine; 2005 May; 23(27):3545-54. PubMed ID: 15855013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM; Corthésy B; Merkle HP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
    Mueller M; Schlosser E; Gander B; Groettrup M
    Int J Cancer; 2011 Jul; 129(2):407-16. PubMed ID: 21207410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple antigen peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice.
    Ali R; Kumar S; Naqvi RA; Sheikh IA; Rao DN
    Int Immunopharmacol; 2013 Jan; 15(1):97-105. PubMed ID: 23174507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses.
    Newman KD; Sosnowski DL; Kwon GS; Samuel J
    J Pharm Sci; 1998 Nov; 87(11):1421-7. PubMed ID: 9811500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.
    Julier Z; de Titta A; Grimm AJ; Simeoni E; Swartz MA; Hubbell JA
    Vaccine; 2016 May; 34(21):2453-2459. PubMed ID: 27016652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
    Jiang W; Gupta RK; Deshpande MC; Schwendeman SP
    Adv Drug Deliv Rev; 2005 Jan; 57(3):391-410. PubMed ID: 15560948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response.
    Fischer S; Schlosser E; Mueller M; Csaba N; Merkle HP; Groettrup M; Gander B
    J Drug Target; 2009 Sep; 17(8):652-61. PubMed ID: 19622019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen.
    Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK
    Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity.
    Heit A; Schmitz F; Haas T; Busch DH; Wagner H
    Eur J Immunol; 2007 Aug; 37(8):2063-74. PubMed ID: 17628858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
    Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.